DeepMed Research

Ascletis Pharmaceuticals Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate Safety of ASC40 Tablets in Patients with Moderate to Severe Acne Vulgaris

Phase 3

Active, not recruiting

Conditions: Acne

Interventions: Drug: ASC40

First Posted Date: 2024-02-08

Last Posted Date: 2025-03-12

Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Target Recruit Count: 240

Registration Number: NCT06248008

Locations: 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China

A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Phase 3

Active, not recruiting

Conditions: Acne

Interventions: Drug: ASC40

First Posted Date: 2024-01-05

Last Posted Date: 2024-11-22

Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Target Recruit Count: 480

Registration Number: NCT06192264

Locations: 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China

Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
COVID-19

Interventions: Drug: RTV tablets
Drug: ASC11 tablets
Drug: Placebo

First Posted Date: 2023-02-08

Last Posted Date: 2024-11-13

Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Target Recruit Count: 72

Registration Number: NCT05718518

Locations: 🇨🇳
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

Phase 1

Withdrawn

Conditions: SARS CoV 2 Infection

Interventions: Drug: Placebo
Drug: ASC10

First Posted Date: 2022-10-27

Last Posted Date: 2024-11-01

Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT05596045

Locations: 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸
Aga Clinical Trials, Hialeah, Florida, United States

Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects

Phase 1

Completed

Conditions: SARS CoV 2 Infection

Interventions: Drug: Placebo
Drug: ASC10

First Posted Date: 2022-08-31

Last Posted Date: 2022-12-16

Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Target Recruit Count: 72

Registration Number: NCT05523141

Locations: 🇨🇳
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

Phase 2

Completed

Conditions: HIV-1-infection
HIV Infections
PD-L1 Gene Mutation

Interventions: Drug: ASC22 1mg/kg
Drug: ASC22 2.5mg/kg
Drug: Antiretroviral Therapy
Drug: Placebo

First Posted Date: 2022-04-15

Last Posted Date: 2024-11-25

Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Target Recruit Count: 19

Registration Number: NCT05330143

Locations: 🇨🇳
The Fifth Medical Center of the General Hospital of the Peoples Liberation Army, Beijing, Beijing, China

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Phase 3

Active, not recruiting

Conditions: Recurrent Glioblastoma

Interventions: Drug: ASC40 tablets
Drug: Placebo tablets
Drug: Bevacizumab

First Posted Date: 2021-11-12

Last Posted Date: 2024-10-31

Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Target Recruit Count: 136

Registration Number: NCT05118776

Locations: 🇨🇳
Beijing Tiantan Hospital，Capital Medical University, Beijing, Beijing, China

Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV

Phase 2

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: ASC42 10mg
Drug: ASC42 15mg
Drug: ih PEG-IFN α-2a
Drug: Placebo
Drug: Entecavir

First Posted Date: 2021-11-04

Last Posted Date: 2024-04-04

Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Target Recruit Count: 43

Registration Number: NCT05107778

Locations: 🇨🇳
NanFang Hospital of Southern Medical University, Guangzhou, Guangdong, China

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Drug: ASC40 75mg
Drug: ASC40 25mg
Drug: ASC40 50mg
Drug: Placebo

First Posted Date: 2021-11-02

Last Posted Date: 2025-05-16

Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Target Recruit Count: 180

Registration Number: NCT05104125

Locations: 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China

Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ASC42
Drug: Placebo

First Posted Date: 2021-07-16

Last Posted Date: 2022-06-30

Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT04965337

Locations: 🇨🇳
Xiangya Boai Rehabilitation Hospital, Changsha, Hunan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy